The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to import certain FDA-approved prescription drug and biological products from Canada. Pharmacists and wholesalers could co-sponsor the programs, which would have to demonstrate that the imported products pose no additional risk to public health and safety and would cost consumers significantly less. The agency also issued draft guidance describing procedures for drug makers importing foreign-made prescription drug and biological products approved by the FDA. FDA will accept comments on the proposed rule for 75 days and on the draft guidance for 60 days after their publication in the Dec. 23 Federal Register. 

Related News Articles

Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
Pictured, from left to right: Peter Adamson, chair of the Children’s Oncology Group at the Children’s Hospital of Philadelphia; Brian Marden, chief…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe…
Headline
The Food and Drug Administration approved a record high 1,171 generic drugs (935 full approvals and 236 tentative approvals) in fiscal year 2019, the agency…
Headline
The AHA and six other organizations today submitted comments to the Drug Enforcement Administration on its proposed rule regarding controlled substances quotas…
Headline
A bipartisan group of 92 members of Congress yesterday urged the Food and Drug Administration to prioritize the release of an interagency task force report on…